Two types of drug-resistant hepatitis B viral strains emerging alternately and their susceptibility to combination therapy with entecavir and adefovir.
Abstract: At that time, rtA181T was undetectable and the virus with rtM204V and rtL180M became predominant.
Abstract: Combination therapy with ETV and ADV might have been effective because these drugs share therapeutic roles, that is, ETV affects the rtA181T-related virus and ADV affects the rtM204V-related virus.
Abstract: Initial 3TC monotherapy offered little benefit and 3TC resistance was established by the virus with rtA181T and not rtM204V/I.
Abstract: Thus, two kinds of
Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir.
Abstract: Combination treatment including potent antiviral agents should be recommended for patients with pre-existing rtM204V/I mutations.
Abstract: ETV resistance mutations (rtL180M+rtT184I/L[rtS202G]+rtM204V) were detected in five patients with pre-existing rt204 mutations.
Abstract: Relative abundances of rtM204V/I mutations in total viral populations gradually increased under ETV rescue, whereas those with rtA181V/T and
Short communication: transmission of hepatitis B viruses with lamivudine resistance mutations in newly diagnosed HIV individuals.
PMID: 20001517
2009
AIDS research and human retroviruses
Abstract: Two HIV/HBV-coinfected patients showed the lamivudine resistance mutation M204V in HBV while no drug resistance mutations were recognized in HIV.
New approaches in the management of chronic hepatitis B: role of tenofovir.
Method: In one patient a HBV subpopulation with mutations rtM204V, rtL180M, and rtA194T could be detected.
Method: In vitro studies show that the rtA194T mutation alone resulted in a 7.6-fold decrease in susceptibility, but in conjunction with rtM204V and rtL180M led to a more than 10-fold decrease in susceptibility to TDF.
Method: The other patient presented with mutations in the HBV polymerase of rtM204V, rt PMID: 17573951
2008
Hepatology research
Abstract: However, load changes for rtM204I alone were greater than those for the rtM204I + rtM204V mixed-type (P = 0.042, at both 40 and 52 weeks).
Abstract: Load changes in rtM204I and rtM204V with G1896A tended to be greater than those without.
Abstract: RESULTS: Changes in viral loads of rtM204I and rtM204V were similar.
Abstract: Viral changes in YMDD mutants (rt PMID: 17962902
2008
Infection
Abstract: We report an unusual case of a male adult patient who showed a prolonged persistence of the M204I mutation up to 24 months after lamivudine withdrawal followed by the emergence of new distinct YMDD mutants (namely M204V, V207L).
Lamivudine resistance and other mutations in the polymerase and surface antigen genes of hepatitis B virus associated with a fatal hepatic failure case.
PMID: 18171343
2008
Journal of gastroenterology and hepatology
Abstract: After 32 months, the rtM204V mutation was predominant, accompanied by the lamivudine-resistant rtL180M mutation.
Abstract: BACKGROUND AND AIM: Resistance to lamivudine therapy of chronic hepatitis B virus (HBV) infection occurs by mutation in the YMDD motif of the reverse transcriptase (rt) domain (rtM204V/I) of the virus polymerase, and is usually accompanied by rtL180M mutation.
Hepatitis B virus genotypes and resistance mutations in patients under long term lamivudine therapy: characterization of genotype G in Brazil.
Abstract: All three showed the double mutation L180M/M204V and displayed a large genetic divergence when compared with other full-length genotype G isolates.
Abstract: Fifteen patients showed the L180M/M204V lamivudine resistant double mutation.
Introduction: More than 90% of the HIV-HBV co-infected patients under lamivudine treatment display the double resistant mutation rtL180M/rtM204V.
Introduction: These mutations usually affect the YM
Result: Fifteen patients showed the well-known double rtL180M/rtM204V mutation.
Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B.
Abstract: RESULTS: Clonal analysis revealed the co-localization on the same HBV genome of rtA181T/V with rtN236T, but not with rtM204V/I mutations following lamivudine, adefovir or lamivudine+adefovir breakthrough.
HBV mutation literature information.
PMID: 
2009
Antiviral therapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT